Considering the low sensitivity and limited specificity of classic biomarkers, including TMB and PD-L1, to identify responders to pembrolizumab caused by the multifactorial tumor-specific mechanisms of response (Banchereau et al., 2021; Litchf ield et al., 2021), we conducted WGCNA in an anti-PD-1 cohort (GSE91061) to identify the key modules significantly related to the response to immune checkpoint blockade therapy. The gene discussed is PDCD1; the disease is neoplasm.